Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TS...d that John Docherty, president and chief operatin...6th annual Investor Summit on November 10, 2009 at...r. Docherty will provide an overview of the Compan...nd Topical Interferon Alpha-2b. The slide show po...
(Date:11/6/2009)... ,, 3Q09 Corporate...a(TM) E.U. Marketing Authorization to Astellas Pha...mercial readiness activities Expanded management ...ng; and Director, Commercial Operations Appointed...t Committee chairman , Upcoming 2009 Milest...
(Date:11/6/2009)...PRNewswire/ -- Intarcia Therapeutics, Inc. deliver...#174; continuous delivery of exenatide) program fo...nual Diabetes Technology Meeting in San Francisco,...prnh/20050301/SFTU126LOGO ) ,, Continuous Sub...s Plasma Glucose, HbA1c and Reduces Weight in a 28...
(Date:11/5/2009)... GenVec, Inc. (Nasdaq: ...he third quarter ended September 30, 2009. GenVec ...re) for the three months ended September 30, 2009 ...share) in the comparable quarter of 2008. For the ... loss was $14.1 million ($0.15 per share), compare...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...ns, and great differences among countries. This i...to use previously collected samples from biobanks ...xtremely complicated to carry out major internatio...hnology, Swedish ethics researchers at the Center ... researchers, put forward a pioneering solution: a...
...w kind of biosensor can tell., A new and deceptiv...s at Vanderbilt University that can measure the in...ical molecules including proteins, sugars, antibod...capability needed to capitalize on the new avenues...ar-plus effort to sequence the human genome. DNA i...
...ound that the body,s innate ability to adapt to re...effective and less costly artificial respirators. ...nduced sedation or paralysis currently necessary f...associative learning, or our innate ability to ada...e described in the September 12 issue of PLoS ONE,...
Other Biology Technology:Long-awaited international ethical guidelines for biobank researchers 2When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 2When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell 3MIT: Leveraging learning for artificial respiration 2
(Date:11/9/2009)...ing Harbor, N.Y. Oncologists have had their hands...have mutations that disable a protein called p53. ...s several cancer-fighting operations within cells.... often cannot be treated. , These tumors might ...ew study from Cold Spring Harbor Laboratory (CSHL)...
(Date:11/9/2009)...versity evolutionary biologists David Queller and ...peration and low conflict between components, from..."organismality," whether that thing is an animal, ...traits scientists use to describe an organism, suc...species, may not be necessary to achieve organisma...
(Date:11/9/2009)...f academic, government and industry researchers ha...esculenta) genome. The project is an important fir...is subsistence crop and addressing some of the man... world. , Cassava is a root crop that serves as ...people each day. Although it has many properties t...
Breaking Biology News(10 mins):CSHL study shows that some malignant tumors can be shut down after all 2CSHL study shows that some malignant tumors can be shut down after all 3What is the meaning of 'one'? 2What is the meaning of 'one'? 3Researchers complete draft genome sequence for cassava 2Researchers complete draft genome sequence for cassava 3Researchers complete draft genome sequence for cassava 4Injection May Heal Damaged Heart 52560 1Injection May Heal Damaged Heart 52560 2National Science Foundation Announces 2420M Research Award to South Carolina 52556 1National Science Foundation Announces 2420M Research Award to South Carolina 52556 2National Science Foundation Announces 2420M Research Award to South Carolina 52556 3More than 1 000 Underinsured and Uninsured Individuals Receive Free Dental Care 52553 1More than 1 000 Underinsured and Uninsured Individuals Receive Free Dental Care 52553 2
...) In an epidemiological study, Tufts University re...in a sample of the United States population based...LP) levels in the bloodstream. Plasma PLP is the i... current Recommended Dietary Allowance (RDA) of vi...function and important for maintaining a healthy i...
...reproduce, like all vertebrates, they either lay t... according to new research by a team of Boston Uni...ropsophus ebraccatus) in Panama that reproduces bo...ecision to lay egg masses aquatically in a pond or...ond, where the newly-hatched tadpoles simply fall ...
...quality at beaches along the Great Lakes have prom... safe for recreation. A new collaborative project ...rs when they are faced with deciding whether to cl...rative effort will draw on the expertise of U.S. G...l agencies. , The project has been funded throug...
Other Biology News:Study identifies trends of vitamin B6 status in US population sample 2Study identifies trends of vitamin B6 status in US population sample 3Reproductive plasticity revealed: Neotropical treefrog can choose to lay eggs in water or on land 2To swim or not to swim? 2
Anti-Human sRANKL Polyclonal Antibody, Biotin Conjugated from Cell Sciences
Mouse Anti-Human Procollagen Type I C-Peptide (PIP) Monoclonal Antibody, Unconjugated, Clone PC5-5 from QED Bioscience Inc.
Goat Anti-Human Factor VIII Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Mouse sRANKL Antibody, Biotin Conjugated from Cell Sciences
Biology Products: